Figure 1.

(A) Trial profile and (B) DDR gene alterations in the intention-to-treat population (n=98)

DDR=DNA damage response. CTC=circulating tumour cell. *Non-mutually exclusive subgroups: one patient had BRCA1/2, CDK12, and other mutations, and two patients had both PALB2 and other mutations (included in each subgroup). †The BRCA2 K3226* variant is supposedly non-pathogenic¹⁹ and was therefore not considered sufficient for patients to be considered eligible; however, one patient with a BRCA2 K3226* variant was included because of evidence of concomitant loss of the contralateral allele.